Accessibility Page Navigation
Style sheets must be enabled to view this page as it was intended.
The Royal College of Psychiatrists Improving the lives of people with mental illness


Psychopharmacology Committee

About us




About the committee

Contact the committee

Contact the committee c/o Stella Galea, Faculty & Committee Manager



Professor David Baldwin MA DM FRCPsych FHEA

David BaldwinDavid Baldwin is Professor of Psychiatry and Head of the Mental Health Group in the Clinical and Experimental Sciences Academic Unit of the Faculty of Medicine at the University of Southampton in the UK. He trained in medicine at Charing Cross Hospital Medical School, in psychiatry at St Mary's Hospital Medical School and the Maudsley Hospital, and in medical humanities at Birkbeck College. He is an Honorary Professor in the University of Cape Town in South Africa and Visiting Professor at Suzhou University Guangji Hospital in China.

He is current Chair of the Psychopharmacology Committee of the Royal College of Psychiatrists, Past President of Depression Alliance, a Medical Patron of Anxiety UK, Editor-in-Chief of Human Psychopharmacology, and author of over 260 full articles in peer-reviewed scientific journals.

Professor Baldwin aims to improve clinical outcomes in mood and anxiety disorders: by investigating the role of neurobiological and psychological factors in causing and maintaining illness; through improving trial design when evaluating efficacy and tolerability of treatment interventions; by assessing the effectiveness and acceptability of treatment interventions in wider clinical practice; through identifying more accurately those patient groups at particular risk of poor outcomes; and by offering a tertiary referral specialist clinical service to patients with chronic and treatment-resistant conditions.

Declaration of interests:

Personal pecuniary interests: In the last three years (September 2014–August 2017), I have received honoraria for giving educational lectures in meetings organised by AstraZeneca, Janssen, H. Lundbeck A/S, Pierre Fabre and Pfizer. I have received financial support from the Ministry of Defence relating to my membership of its Research Ethics Committee. I have also received financial support from the Wiley publishing company relating to my editorship of the Human Psychopharmacology journal.

Personal family interest: My wife has received a personal honorarium for participating in an advisory board organised by H. Lundbeck A/S.

Non-personal pecuniary interest: In the last three years, my employer has received reimbursement for my time spent in attendance at advisory board meetings organised by Liva Nova and Mundipharma.

Personal non-percuniary interest: I am a Medical Patron of Anxiety UK and the University-nominated Governor on the Board of Southern Health NHS Foundation Trust (April 2017 onwards).

Professor Allan Young MB ChB, MPhil, PhD, FRCPsych, FRCPC

Professor Allan Young

Chair of Mood Disorders, Director of the Centre for Mental Affective Disorders, Department of Psychological Medicine, King’s College London, UK

Professor Allan Young holds the Chair of Mood Disorders at King’s College London where he is also Director of the Centre for Affective Disorders within the Department of Psychological Medicine in the Institute of Psychiatry. He has held academic appointments at the Universities of Oxford, Newcastle upon Tyne (latterly holding the Chair of General Psychiatry at Newcastle), UBC, Vancouver, Canada, where he held the Leading Edge Endowment Fund Endowed Chair in Research in the Department of Psychiatry and was also the Director of the Institute of Mental Health and Imperial College London where he held the Chair of Psychiatry and was Director of the Centre for Mental Health.

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, and the Canadian Institutes for Heath Research (CIHR), the National Institutes of Health (USA) and numerous other funding agencies. He has published over 300 peer-reviewed publications and a number of books about psychopharmacology and affective disorders including ‘Bipolar disorders: basic mechanisms and therapeutic implications’ (2nd Ed.) with JC Soares, and ‘Practical management of bipolar disorder’ with IN Ferrier and E Michalak (Cambridge University Press, 2010).

Professor Young is a member of a number of editorial boards and is a member of numerous professional and scientific societies. He is currently Treasurer of the International Society for Affective Disorders and Chair of the Psychopharmacology group of the Royal College of Psychiatrists.  Professor Young also acts as an expert witness.

Declaration of Interests: 

Employed by King’s College London; Honorary Consultant SLaM (NHS UK).

Paid lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders.

No share holdings in pharmaceutical companies.

Lead Investigator for Embolden Study (AZ), BCI Neuroplasticity study and Aripiprazole Mania Study.

Investigator initiated studies from AZ, Eli Lilly, Lundbeck, Wyeth.

Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK).


Professor Thomas R. E. BarnesProfessor Tom Barnes,  MD FRCPsych DSc.

I am Professor of Clinical Psychiatry at Imperial College, London, Honorary Consultant Psychiatrist at the West London Mental Health NHS Trust, and joint-head of the Prescribing Observatory for Mental Health (POMH-UK).

In 1987, I set up one of the first tertiary-referral services for treatment-resistant schizophrenia. The main focus of my clinical research over the last 30 years has been schizophrenia, with a particular interest in the rational treatment of the condition. I have led investigations that have covered psychological and pharmacological treatment interventions for the condition and investigated antipsychotic drug side effects (particularly extrapyramidal movement disorders; the reliability, validity and clinical utility of the Barnes Akathisia Rating Scale have been independently demonstrated, and it is the scale most frequently used to assess this condition, world-wide), as well as phenomenology, neurocognition and comorbid substance use, including a Wellcome-funded, first-episode psychosis study. My work has generated over 250 publications.

Recent research experience includes PI for the CUtLASS trial, and chair of the IDMECs for the BALANCE and CEQUEL trials. I am currently CI for the HTA-funded ACTIONS and AMICUS trials, PI for the BeneMin study, and chair of the Trial Steering Committees for the NESS and CIRCLE studies. I am a past member of the Committee on Safety of Medicines, past Chair of the Royal College of Psychiatrists’ Special Interest Group in Psychopharmacology, and past President of the British Association for Psychopharmacology. I was a member of the NICE schizophrenia guideline development group (and chair of the pharmacology subcommittee) in 2002 and for the guideline update in 2009.

Dr David Christmas Dr David Christmas

I am a Consultant Psychiatrist in the Advanced Interventions Service, a Scottish National Specialist Service for the assessment and treatment of chronic, treatment-refractory depression and Obsessive-Compulsive Disorder (OCD). I work in Dundee and have been in my current post since 2006. Prior to this, I was a clinical lecturer in the University of Dundee (2003-2006), and I did his basic specialist training in Forth Valley.

I was previously Financial Officer for the Royal College of Psychiatrists in Scotland and I am one of the Academic Secretaries for the Royal College of Psychiatrists Faculty of General Adult Psychiatry, responsible for the academic programme of the GAP Faculty Conferences.

I also sit on the steering group overseeing the Scottish Suicide Information Database (ScotSID). Within NHS Tayside, I co-chaired a steering group for mental health information systems and continues to be involved in a range of quality improvement and mental health performance roles.

My research interests include the neuroimaging of mood disorders, and the neurosurgical treatment of chronic, treatment-refractory mood disorders and OCD. He often speaks about the use of antidepressants, the management of treatment-refractory mood disorders, and the importance of evidence-based approaches to the treatment of mental disorder. I am currently involved in looking at the evidence base for psychological treatments for severe and/or chronic depression and OCD.

Declaration of Interests:

Employment: I am employed by NHS Scotland to deliver specialist assessment and treatment (including neurosurgical treatment) for depression and OCD.

Research: I have been part of two research projects for which financial support was paid to my institution (University of Dundee) by medical device companies (Cyberonics, Inc., 2008; and St. Jude Medical, 2013).

Education and training: I have received support to attend educational meetings in the last 5 years (Medtronic, 2009), but no support has been received from companies in the last five years. I have received expenses associated with speaking from PULSE and Briefing Media Ltd. (2013). An honorarium for speaking from Lundbeck (2012) was donated to charity. I have received payment from the Royal College of Psychiatrists (2012) and the British Association of Psychopharmacology (2014) to develop online learning modules.

Other payments: I have not received any payments or consulting fees from pharmaceutical companies in the last five years and I do not sit on any advisory boards.

Shares and patents: I have no shareholdings, patents, or financial interests relating to pharmaceutical or medical device companies.

Ellisiv ClarkeMs Ellisiv Clarke

Ellisiv is a fifth-year medical student at Newcastle University, where she is currently intercalating in a Masters by Research. Ellisiv holds the post of Medical Student Representative on the Psychiatric Trainees Committee, and represents them at the Psychopharmacology Committee.

Ellisiv's interests include child and adolescent mental health, and aims to promote awareness and interest in psychiatry and mental health in her role as president of Newcastle University's Psychiatry Society.

Ellisiv has no declarations of interest.


Professor Oliver Howes BM BCh MA MRCPsych PhD DM

Oliver HowesOliver Howes is Professor of Molecular Psychiatry at the Institute of Psychiatry, Psychology and London Institute of Medical Sciences, Imperial College, London. His clinical work is as Consultant Psychiatrist at The Maudsley Hospital where, amongst other things, he runs a service for people with refractory psychoses.

His research interests centre on the causes and treatment of psychosis. His recent work has focussed on understanding the role of dopamine and neuroinflammation in the development of psychosis, the effects of antipsychotic drugs on the nervous and endocrine systems, & the causes of cognitive impairment in schizophrenia. This work has been recognised through a number of awards including the Schizophrenia International Research Society Rising Star Award 2013, European Psychiatric Association Biological Psychiatry Prize (2012), the Royal Society of Medicine Psychiatry Prize (2010), Royal College of Psychiatrists research prize (2005), and the British Association of Psychopharmacology Clinical Psychopharmacology Prize (2007). He was made an honorary associate of the European College of Neuropsychopharmacology in 2006.

Other career highlights include working as a junior potato scrubber on a farm. He spends his spare time selflessly trying to find the world’s best ice cream.

Declaration of Interests:

Employed by King’s College London and Honorary Consultant at SLaM (NHS UK).

No share holdings in pharmaceutical or medical device companies.

Has received funding from Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche for investigator initiated studies and/or for participation in advisory boards, speaker bureau and/or educational events. 

Main grant funding (past and present): MRC (UK), Wellcome Trust, and European Union.

Professor R Hamish McAllister-Williams BSc, MB, ChB, Ph.D., M.D., FRCPsych

Dr R Hamish McAllister-Williams

Reader in Clinical Psychopharmacology, Institute of Neuroscience, Newcastle University and Honorary Consultant Psychiatrist Regional Affective Disorders Service, Northumberland Tyne and Wear NHS Foundation Trust.

Professor McAllister-Williams has been employed by Newcastle University since 1995, initially as a Clinical lecturer, then as an MRC Clinician Scientist Fellow at Senior Lecturer level and from 2004 as a Reader in Clinical Psychopharmacology. Clinically, he is the lead consultant in the tertiary level Regional Affective Disorders Service based in Newcastle. This is the oldest and one of the largest such service in the UK providing outpatient and inpatient services for patients with treatment refractory mood disorders. Referrals to the service are received from across the UK to the service. Professor McAllister-Williams research focuses on the pathophysiology and treatment of both bipolar and unipolar affective disorders. He is a past General Secretary of the British Association for Psychopharmacology (BAP) and was appointed in 2012 as the BAP Director of Education. He is a major contributor to their CPD programme.

Declaration of Interests:

Professor McAllister-Williams has received speaker and consultancy fees, support for attending meetings and independent investigator led research awards from a number of pharmaceutical companies over several years including AstraZeneca, Bristol Myers-Squibb, Cyberonics, Eli Lilly, Ferrer, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck Sharp & Dohme, My Tomorrows, Otsuka, Pfizer, Roche, Servier, SPIMACO, Sunovion and Wyeth. The vast majority of such monies have been paid to his employer, Newcastle University. Neither he nor any of his immediate family hold any shares in, or have on-going financial relationships with, any pharmaceutical company.

Dr Adrian JamesDr Adrian J B James MB BS FRCPsych MSc

Adrian has been Registrar of the College since 2015.  In this role he has overall responsibility for policy, public education, revalidation and membership engagement.  In his role as College Registrar he is prioritising recruitment and  communicating with the public, media and system leaders to ensure parity of esteem becomes a reality on the ground.

Adrian is Consultant Forensic Psychiatrist at Langdon Hospital in Dawlish, Devon. He is a former Medical Director of Devon Partnership NHS Trust and Founding Chair of the School of Psychiatry at the Peninsular Deanery (2006-2008).

He was the elected Chair of the South West Division of the Royal College of Psychiatrists (2007-2011) and sat on the College Council in this capacity. In 2010 he was appointed Chair of the Westminster Parliamentary Liaison Committee of the Royal College of Psychiatrists (attending the three main Party Conferences 2011-14 in this capacity).

He was Clinical Director for Mental Health, Dementia and Neurology, working for NHS England South West (2013-2015, interim from 2012-13). He has also acted as a Reviewer and Clinical Expert for the Healthcare Commission and its successor organisation the Care Quality Commission (CQC).

Dr Ahmed Shoka

Dr Ahmed Shoka

Consultant in General Adult Psychiatry, North Essex Partnership University NHS Foundation Trust. I am also an honorary lecturer at the School of Health & Human sciences , Essex University. I have always viewed the art of psychopharmacology as the sclapel in the hands of a crafty surgeon. I run a Metabolic Clinic at my Trust to sddress issues of Physical health for those who suffer from Severe Mental Illness (SMI. I have a specialised training in the diagnosis and treatment of Adult ADHD and consequently I run a clinic in this specialised field.

I have a keen interest in Compliance, Concordance and Adherence when it comes to prescribing. I have publications in OCD, Depot antipsychotics and Physiccal Health monitoring. The relationship between Depression, Anxiety and Pain attracts my attention both clinically and from the research point of view. I am continuously developing my knowlegde and skills in the "interface between medical ethics and the law.


Declaration of Interests:

I have no direct business or shares with any pharmaceutical company.
I receive no grants for research.
I get paid agreed honoraria for delivering educational and not promotional talks both nationally and internationally.



Login - Members Area

If you don't have an account please Click here to Register

Make a Donation